Evidence map›Paper›PMID 36230945›Full record

ArticleCells2022

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.

Ashleigh Hull, Yanrui Li, Dylan Bartholomeusz, William Hsieh, William Tieu, Tara L Pukala, Alexander H Staudacher, Eva Bezak

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026
    Review
  3. Development of [EJNMMI radiopharmacy and chemistry · 2023
    Article
  4. In vitro characterisation of [EJNMMI radiopharmacy and chemistry · 2023
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Ashleigh HullAllied Health and Human Performance Academic Unit, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0003-3361-997X
Yanrui LiAllied Health and Human Performance Academic Unit, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Dylan BartholomeuszDepartment of PET, Nuclear Medicine & Bone Densitometry, Royal Adelaide Hospital, SA Medical Imaging, Adelaide, SA 5000, Australia.
William HsiehAllied Health and Human Performance Academic Unit, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
William TieuMolecular Imaging and Therapy Research Unit, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
Tara L PukalaSchool of Physical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.ORCID 0000-0001-7391-1436
Alexander H StaudacherAdelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia.
Eva BezakAllied Health and Human Performance Academic Unit, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0002-1315-1735
Royal Adelaide Hospital · AUUniversity of South Australia · AUSouth Australian Health and Medical Research Institute · AUSouth Australia Pathology · AUThe University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucin 1 is a transmembrane glycoprotein which overexpresses cancer-specific epitopes (MUC1-CE) on pancreatic ductal adenocarcinoma (PDAC) cells. As PDAC is a low survival and highly aggressive malignancy, developing radioimmunoconjugates capable of targeting MUC1-CE could lead to improvements in PDAC outcomes. The aim of this study was to develop and perform preliminary testing of diagnostic and therapeutic radioimmunoconjugates for PDAC using an anti-MUC1 antibody, C595. Firstly, p-SCN-Bn-DOTA was conjugated to the C595 antibody to form a DOTA-C595 immunoconjugate. The stability and binding affinity of the DOTA-C595 conjugate was evaluated using mass spectrometry and ELISA. DOTA-C595 was radiolabelled to Copper-64, Lutetium-177, Gallium-68 and Technetium-99m to form novel radioimmunoconjugates. Cell binding assays were performed in PANC-1 (strong MUC1-CE expression) and AsPC-1 (weak MUC1-CE expression) cell lines using

Indexed as

Carcinoma, Pancreatic DuctalImmunoconjugatesPancreatic NeoplasmsAntibodies, MonoclonalCopper RadioisotopesEpitopesGallium RadioisotopesHumansLutetiumMucin-1RadioisotopesTechnetiumAntibodies, MonoclonalCopper-64Copper RadioisotopesEpitopesGallium-68Gallium RadioisotopesImmunoconjugatesLutetiumLutetium-177MUC1 protein, humanMucin-1RadioisotopesTechnetiumC595mucin 1pancreatic cancerradioimmunoconjugates

Identifiers

PMID36230945
PMCPMC9563759
OpenAlexW4297148366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.